SS-31: The Peptide  ‘Mitochondrial Shield’ That May Block Parkinson’s Damage at the Source

SS-31: The Peptide ‘Mitochondrial Shield’ That May Block Parkinson’s Damage at the Source

This is the first dedicated peptide deep dive of The Energy Code — and it starts with arguably the most mitochondrial-centric peptide on the board: SS-31 (Elamipretide). Dr. Mike breaks down a new paper showing how SS-31 may protect neurons in Parkinson’s disease by competing with alpha-synuclein at lipid membranes, slowing toxic aggregation, restoring mitochondrial respiration, and even reducing alpha-synuclein cellular entry. You’ll also hear a key caution: SS-31 appears highly protective at moderate doses, but too much may flip the benefit into harm, reinforcing the “dose makes the medicine” rule in mitochondrial pharmacology.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function

-

Key Quotes From Dr. Mike:

“The future of Parkinson’s therapy may not lie in cleaning up the mess, but rather in providing our neurons with a permanent molecular shield…”

“SS-31 acts as a molecular shield protecting the brain’s energy supply…”

“SS-31 acts as a molecular bouncer, physically evicting alpha-synuclein from lipid membranes…”

“SS-31 substantially prolonged the lag phase of aggregation, essentially stalling the clock on protein buildup.”

“These findings underscore the multifaceted protective role of SS-31 against mitochondrial dysfunction caused by alpha synuclein aggregation... SS-31 reversed this decline with a 10 micromolar dose…”

-

Key Points

  • SS-31 is framed as a mitochondria-first peptide: “restore impaired mitochondrial function” is the headline.
  • Parkinson’s pathology is presented as a cellular power failure inside dopaminergic neurons driven by alpha-synuclein toxicity.
  • SS-31 may act like a “molecular bouncer” — outcompeting alpha-synuclein for anionic lipid membranes and preventing harmful binding/folding.
  • The episode highlights the real-world complication: N-terminal acetylated alpha-synuclein (common in humans) embeds deeper and is harder to displace.
  • SS-31 appears to delay aggregation kinetics (longer “lag phase”) and shift aggregate morphology toward potentially less toxic off-pathway forms.
  • Mitochondrial function was assessed with a Seahorse mito stress test; SS-31 is described as restoring basal/max respiration (at a cited 10 μM dose).
  • Mechanistically, SS-31 is explained as:
    1. Cardiolipin binding → supports OXPHOS efficiency/ATP output
    2. ROS scavenging (tyrosine residue) → reduces oxidative damage
  • SS-31 may also reduce alpha-synuclein oligomer uptake by altering membrane electrostatics (less negative surface charge).
  • A major warning: very high concentrations (described as >100 μM) may trigger apoptosis / reduce viability.
  • Big-picture: SS-31 supports a “prevention-first” strategy — block the lipid–protein interaction upstream, rather than “cleaning up the mess” later.

-

Episode timeline

  • 0:00–0:40 — Why peptides are the next major content focus; why SS-31 is the first peptide deep dive
  • 0:40–3:55 — Paper intro + “SS-31 restores impaired mitochondrial function” framing; what the show will cover and why it matters
  • 3:55–5:44 — Parkinson’s as mitochondrial “power failure”; alpha-synuclein as the driver; SS-31 as a BBB-permeable candidate
  • 5:44–6:58 — Takeaway #1: SS-31 as a “molecular bouncer” displacing alpha-synuclein from membranes (dose-dependent)
  • 6:58–8:16 — Takeaway #2: N-terminal acetylation makes alpha-synuclein “stickier” and harder to displace (real-human relevance)
  • 8:16–9:40 — Takeaway #3: Aggregation kinetics + morphology shifts (stalling the “snowball”)
  • 9:40–11:40 — Takeaway #4–#5: Respiration rescue + membrane/cell-entry effects; the dual mechanism (cardiolipin + ROS)
  • 11:40–13:20 — Dose caution, wrap-up, and the “designer peptides” future-forward conclusion

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

BioLight Labs:

Website

Instagram

BioLight:

Website

Instagram

YouTube

Facebook

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(381)

Mitochondrial Medicine Is Accelerating: 8 New Breakthroughs You Need to Know

Mitochondrial Medicine Is Accelerating: 8 New Breakthroughs You Need to Know

Light just won the Nobel Prize — and at virtually the same time, mitochondrial science is exploding with new discoveries. In this solo episode of The Energy Code, Dr. Mike Belkowski breaks down some o...

8 Loka 55min

Beyond Mitochondria: The Invisible Energy System Running Your Body | Harry Massey

Beyond Mitochondria: The Invisible Energy System Running Your Body | Harry Massey

What if human health is governed by more than chemistry alone? In this episode of The Energy Code, Dr. Mike Belkowski sits down with Harry Massey, pioneer in bioenergetics and founder of NES Health an...

1 Loka 1h 12min

The Missing Link That Could Make Every Peptide Work Better

The Missing Link That Could Make Every Peptide Work Better

Why do some people experience incredible results from peptides while others barely notice a difference? In this episode of The Energy Code, Dr. Mike Belkowski and Don Bailey explore one of the most ov...

24 Syys 1h 25min

The Biggest Peptide Breakthroughs of 2026: MOTS-c, Retatrutide, FDA Shifts & What Happens Next

The Biggest Peptide Breakthroughs of 2026: MOTS-c, Retatrutide, FDA Shifts & What Happens Next

The peptide landscape is evolving faster than ever before — and 2026 may prove to be the biggest turning point yet. In this episode, Dr. Mike Belkowski breaks down the most important developments shap...

17 Syys 34min

The Light System Explained: Can Light, Frequency & Energy Transform Your Health? | Jarrod Barakett

The Light System Explained: Can Light, Frequency & Energy Transform Your Health? | Jarrod Barakett

In this special episode of The Energy Code, Dr. Mike Belkowski sits down with Jarrod Barakett, President of The Light System, to explore the intersection of light frequencies, bioenergetics, cellular ...

10 Syys 1h 13min

10 Breakthrough Mitochondrial Studies That Could Change Medicine Forever

10 Breakthrough Mitochondrial Studies That Could Change Medicine Forever

In this special Research Jamboree episode of The Energy Code, Dr. Mike Belkowski takes listeners on a rapid-fire tour through some of the most exciting mitochondrial research published over the past f...

3 Syys 36min

The Ultimate Guide to Intranasal Peptides: Brain Repair, Focus, Sleep, Longevity & More

The Ultimate Guide to Intranasal Peptides: Brain Repair, Focus, Sleep, Longevity & More

Intranasal peptides have become one of the most exciting frontiers in peptide research — but which ones actually make sense, and why? In this episode, Dr. Mike Belkowski breaks down the science behind...

27 Elo 1h 3min

GLP-1s, Urolithin A & Urolithin B: Uncovering the Mitochondria-Metabolism-Brain Axis

GLP-1s, Urolithin A & Urolithin B: Uncovering the Mitochondria-Metabolism-Brain Axis

Could metabolic aging, chronic anxiety, and depression all share the same biological root? In this episode of The Energy Code, Dr. Mike Belkowski reviews three newly published studies that, when viewe...

20 Elo 45min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
aamukahvilla
vakeva-elama-viisaampi-mieli-vahvempi-keho
psykopodiaa-podcast
rss-kuumilla-aalloilla
rss-pitaisko-erota
meditaatiot-suomeksi
voi-hyvin-meditaatiot-2
rss-uplevel-by-sonja-hannus
rss-pt-paahtio
tiedenaiset-podcast
rss-terapiaklubi
rss-mighty-finland-podcast
junnut-pelissa
rss-pska-juttu
paritellen
rss-narsisti
rss-duodecim-lehti
fitnessvastaanotto
onnen-kuplia